BIOCEPT, INC. (NASDAQ:BIOC) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain OfficersItem 5.02.
On September6, 2017, Edward Neff notified Biocept, Inc. (the “Company”) that, in order to be able to focus more time on other business efforts, he is resigning as a member of the Company’s Board of Directors (the “Board”) and as a member of all committees of the Board, effective as of September8, 2017.
About BIOCEPT, INC. (NASDAQ:BIOC)
Biocept, Inc. is an early commercial-stage molecular oncology diagnostics company. The Company develops and commercializes circulating tumor cell (CTC) and circulating tumor deoxyribonucleic acid (ctDNA), assays utilizing a standard blood sample, or liquid biopsy. The Company’s Target-Selector offering is based on an internally developed, microfluidics-based CTC capture and analysis platform, with enabling features that change how CTC testing can be used by clinicians by providing biomarker detection and monitoring requiring only a standard blood sample. The ctDNA technology enables mutation detection and is applicable to nucleic acid from CTCs or other sample types, such as blood plasma. The Company commercializes its Target-Selector assays for a range of solid tumor indications, such as breast cancer, non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), gastric cancer, colorectal cancer, prostate cancer and melanoma. BIOCEPT, INC. (NASDAQ:BIOC) Recent Trading Information
BIOCEPT, INC. (NASDAQ:BIOC) closed its last trading session up +0.09 at 1.41 with 581,902 shares trading hands.
